Denali Therapeutics (DNLI) News Today

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and eight have assigned a buy recom

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at Leerink Partnrs dropped their FY2025 earnings per share estimates for Denali Therapeutics in a research note issued on Tuesday, September 3rd. Leerink Partnrs analyst M. Goodman now forecasts that the company wil

HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Denali Therapeutics in a report on Wednesday.

Denali Therapeutics (NASDAQ:DNLI) Stock Price Up 3.1%

Principal Financial Group Inc. trimmed its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 3.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,088,537 shar

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) saw a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 8,360,000 shares, a growth of 16.3% from the July 31st total of 7,190,000 shares. Approximately 7.0% of the company's stock are sold short. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 7.3 days.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at Zacks Research upped their Q3 2024 earnings estimates for shares of Denali Therapeutics in a note issued to investors on Monday, August 19th. Zacks Research analyst A. Chakraborty now anticipates that the company will post e

Denali Therapeutics (NASDAQ:DNLI) Reaches New 12-Month High at $25.25

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eight have assigned a buy recomm

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - B. Riley decreased their Q3 2024 earnings per share estimates for shares of Denali Therapeutics in a report released on Monday, August 5th. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of ($0.74) for t

HC Wainwright cut their price target on shares of Denali Therapeutics from $95.00 to $90.00 and set a "buy" rating for the company in a report on Monday.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.10. The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $10.00 million. The business's revenue for the quarter was down 99.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.30 earnings per share.

Citigroup increased their price objective on Denali Therapeutics from $26.00 to $32.00 and gave the company a "buy" rating in a research note on Friday.

Wedbush cut their target price on shares of Denali Therapeutics from $30.00 to $26.00 and set an "outperform" rating on the stock in a research report on Friday.

Price T Rowe Associates Inc. MD decreased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 38.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,594,33

Vanguard Group Inc. lifted its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 1.2% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,968,293 shares of the company's stock after purchasing an additional

Bayesian Capital Management LP acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 21,800 shares of the company's stock, valued at approximately $447,000. A num

Russell Investments Group Ltd. reduced its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 23.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 85,628 shares of the company's stock after selling 25,845 shares during the quarter.

Capital Research Global Investors increased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 107.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,049,957 shares of the company's sto

EP Wealth Advisors LLC purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 40,500 shares of the company's stock, valued at approximately $831,000. Se

Seven Eight Capital LP cut its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 71.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,541 shares of the company's stock after selling 52,046

Edgestream Partners L.P. bought a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 112,118 shares of the company's stock, valued at approximately $2,301,000. Edges

Denali Therapeutics (NASDAQ:DNLI) Sees Strong Trading Volume

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. Th

BNP Paribas Financial Markets lowered its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 62.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 72,105 shares of t

Susquehanna Fundamental Investments LLC purchased a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 211,017 shares of the company's stoc

JPMorgan Chase & Co. boosted their price target on shares of Denali Therapeutics from $28.00 to $29.00 and gave the stock an "overweight" rating in a research note on Wednesday.

Denali Therapeutics (NASDAQ:DNLI) Shares Up 3.6%